Abstract:Cardiovascular diseases persist as a global health challenge that requires methodological innovation for effective drug development. Conventional pipelines relying on animal models suffer from high failure rates due to significant interspecies variation between humans and animal models. In response, the recently enacted Food and Drug Administration Modernization Act 2.0 encourages alternative approaches including induced pluripotent stem cells (iPSCs). Human iPSCs provide a patient-specific, precise, and screenable platform for drug testing, paving the way for cardiovascular precision medicine. This review discusses milestones in iPSC differentiation and their applications from disease modelling to drug discovery in cardiovascular medicine. It then explores challenges and emerging opportunities for the implementation of 'clinical trials in-a-dish'. Concluding, this review proposes a framework for future clinical trial design with strategic incorporations of iPSC technology, microphysiological systems, clinical pan-omics, and artificial intelligence to improve success rates and advance cardiovascular healthcare. The landscape of iPSC technology is swiftly shifting from 2D models to more sophisticated 3D structures that recapitulate cardiac biology and diseases with unprecedented precision. This transformation presents exciting opportunities to conduct clinical trials 'in-a-dish'. By harnessing patient-specific iPSC derivatives like cardiac organoids, trialists may be able to effectively filter out toxic drugs, monitor drug behaviours, and select trial participants who respond to drug candidates. Furthermore, the integration of cutting-edge synergistic technologies, such as artificial intelligence, microphysiological systems, and clinical pan-omics, is instrumental in facilitating the implementation of clinical trials 'in-a-dish', ultimately leading to improved success rates.

Next-Gen Therapeutics: Pioneering Drug Discovery with iPSCs, Genomics, AI, and Clinical Trials in a Dish

Induced Pluripotent Stem Cells As a Disease Modeling and Drug Screening Platform

Inducing Pluripotency for Disease Modeling, Drug Development and Craniofacial Applications.

Human-Induced Pluripotent Stem Cell-Based Differentiation of Cardiomyocyte Subtypes for Drug Discovery and Cell Therapy

Clinical trials in-a-dish for cardiovascular medicine

Current Challenges of iPSC-Based Disease Modeling and Therapeutic Implications

Human and Machine Intelligence Together Drive Drug Repurposing in Rare Diseases

Can stem-cell-derived models revolutionize drug discovery?

Induced Pluripotent Stem Cell Technology: A Paradigm Shift in Medical Science for Drug Screening and Disease Modeling

A practical guide to induced pluripotent stem cell research using patient samples

Drug screening for human genetic diseases using iPSC models

Artificial Intelligence for Drug Discovery: Are We There Yet?

Induced pluripotent stem cells for neural drug discovery

iPSC-Derived Organoids as Therapeutic Models in Regenerative Medicine and Oncology

Future Perspective of Induced Pluripotent Stem Cells for Diagnosis, Drug Screening and Treatment of Human Diseases.

One Step Into the Future: New iPSC Tools to Advance Research in Parkinson's Disease and Neurological Disorders

Application Prospect of Induced Pluripotent Stem Cells in Organoids and Cell Therapy

Induced Pluripotent Stem Cells in Drug Discovery and Neurodegenerative Disease Modelling

Human iPSC-Based Modeling of Central Nerve System Disorders for Drug Discovery

Pluripotent stem cells for neurodegenerative disease modeling: an expert view on their value to drug discovery

iPSC-cardiomyocytes in the preclinical prediction of candidate pharmaceutical toxicity